How Does Glycaemic Control Impact Complications in Type 2 Diabetes?
Summary of The UK Prospective Diabetes Study (UKPDS).
The UK Prospective Diabetes Study (UKPDS) is a landmark study that has significantly influenced the management of type 2 diabetes (T2D). The study by Stratton et al., published in BMJ in 2000, explores the relationship between glycaemic control and the risk of macrovascular and microvascular complications in patients with T2D. This summary highlights the key findings and their implications for clinical practice.
The UKPDS was a prospective observational study involving 4,585 patients with newly diagnosed T2D. The study aimed to determine how long-term glycaemic control, measured by HbA1c levels, affects the incidence of various diabetic complications. Data were collected over a median follow-up period of 10 years.
Key Highlights
- Risk Reduction:
Each 1% reduction in updated mean HbA1c was associated with significant reductions in the risk of complications:
- 21% reduction in any diabetes-related endpoint.
- 21% reduction in diabetes-related deaths.
- 14% reduction in myocardial infarction.
- 37% reduction in microvascular complications.
- Hide text
- No Threshold Effect:
The study found no specific HbA1c threshold below which the risk of complications markedly decreased. Instead, the risk of complications continuously decreased with lower HbA1c levels.
- Consistent Benefits:
The benefits of improved glycaemic control were consistent across different types of complications, emphasizing the importance of maintaining lower HbA1c levels to reduce overall risk.
Conclusion
The UKPDS demonstrates that better glycaemic control significantly reduces the risk of both macrovascular and microvascular complications in patients with T2D. The findings support the goal of achieving and maintaining lower HbA1c levels to minimize the risk of complications and improve patient outcomes.
Clincal implications for General Practice
Healthcare providers should focus on:
By prioritizing these strategies, healthcare providers can help patients with T2D achieve better glycaemic control and reduce the incidence of diabetes-related complications.
Pour accéder à cette page, vous devez vous connecter. Si vous n'avez pas de compte, vous pouvez en créer un ici.
Références
-
Stratton, I. M., et al. (2000). Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ, 321, 405-412
Articles liés
Act early, think holistically for your patients with Type 2 diabetes at very high cardiovascular risk
People with type 2 diabetes and atherosclerotic cardiovascular disease face a high risk of cardiovascular events, yet many remain undertreated.1 The EASD/ADA 2022 and ESC 2023 guidelines for the management of type 2 diabetes urge early insulin initiation and intensive lipid lowering through a holistic approach. Managing both glycemia and lipids together is key to preventing CV events in people with type 2 diabetes.2,3
Pooled analysis: Interventional and observational studies
A post-hoc pooled analysis to evaluate efficacy and safety of insulin glargine 300 U/mL in insulin-naïve people with type 2 diabetes with/ without prior use of glucagon-like peptide-1 receptor agonist therapy.1
Les contenus accessibles par ce site sont destinés exclusivement aux Professionnels de Santé.
Les contenus accessibles par ce site sont destinés
exclusivement aux Professionnels de Santé.
Sanofi met a votre disposition, sur un portail unique dédié aux professionnels de santé, des contenus exclusifs comprenant des contenus scientifiques et des outils pour votre pratique quotidienne.